Priming Mesenchymal Stem Cells for Exosome Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for scaling up production of mesenchymal stem cell-derived exosomes for therapeutic applications are limited by the variability of exosome cargo due to priming agents in culture and the inability to achieve sufficient commercial-scale production.
Innovation Solution
A method involving expanding mesenchymal stem cells in culture, priming them with cell-derived conditioned medium and defined agents like Nrf2 activators, and collecting the conditioned medium to produce exosomes with enhanced therapeutic efficacy, characterized by specific cargo profiles such as higher NGF and HGF expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional MSC expansion methods are used, then large quantities of MSCs can be produced, but the exosome cargo composition becomes variable and therapeutic efficacy is reduced
Solution Approach 1:
The patent applies preliminary action by pre-priming MSCs with defined agents (Nrf2 activators, SIRT1 activators, ATRA) before exosome production. This priming step establishes a stable transcriptional profile and cargo composition in advance, ensuring that subsequent expansion and production processes maintain consistent exosome quality and therapeutic efficacy.
2Productivity
If MSCs are expanded to large quantities for commercial scale, then sufficient exosome supply is achieved, but the complexity of maintaining consistent cargo composition increases
Solution Approach 1:
The patent applies parameter changes by using defined priming agents with specific molecular mechanisms (Nrf2 activation, SIRT1 activation, ATRA treatment) to control MSC transcriptional profiles. These parameter changes at the molecular level enable consistent exosome cargo composition across large-scale production, simplifying process control while maintaining productivity.
3Reliability
If priming agents are used to enhance exosome cargo, then therapeutic efficacy is improved, but the risk of unexpected effects on MSC activity increases
Solution Approach 1:
The patent uses defined priming agents as intermediaries that act through specific molecular pathways (Nrf2, SIRT1, retinoic acid receptors) to modulate MSC behavior. These intermediaries provide controlled and predictable effects on exosome cargo composition, enhancing therapeutic efficacy while minimizing unexpected harmful effects through well-characterized mechanisms of action.
Data Source
AI summary
There is provided herein methods generating a population of primed mesenchymal stem cell-derived exosomes. A method in accordance with the disclosure may comprise expanding a population of mesenchymal stem cells (MSCs) in culture, administering one or more priming agents in the culture to prime the population of MSCs and obtain a population of primed MSCs: growing the population of die primed MCSs in culture to produce a primed-MSC-derived conditioned medium; collecting the primed MSC-conditioned medium; and purifying a population of exosomes from the primed MSC-conditioned medium. The one or more priming p agents may comprise a conditioned media derived from a population of stem cells different from the population of MSCs, a Nrf2 activator, or a combination thereof. There is also provided herein methods of treating tissues such as cornea and liver using the population of exosomes from the primed MSC-conditioned medium.